Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of HebaBiz Biotech.

    Client Virtual Booth

    HEBABIZ BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    HebaBiz Biotech
    China Flag
    Country
    Country
    China
    Address
    Address
    402, Block 7, No. 20 Shengmingyuan Road, Zhongguancun Life Science Park, Changping District, Beijing
    Telephone
    Telephone
    010-53937755
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.huibaoyuan.com.cn/en/?redirect=0
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    R&D Milestone: HebaBiz Biotech's Application for Phase III clinical trial in China for Clevudine (L-FMAU), An Anti-Hepatitis B Virus Drug Candidate Unde...

    Details:

    L-FMAU (Clevudine) is a synthetic β-L nucleoside analogue introduced from Yale University and HebaBiz Biotech obtained its exclusive license for anti-hepatitis B virus in Greater China. L-FMAU as a new generation best-in-class anti-HBV new drug.


    Lead Product(s): Clevudine

    Therapeutic Area: Infections and Infectious Diseases Product Name: L-FMAU

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 15, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HebaBiz Biotech's Anti-Cancer Drug Candidate Under Development Siroquine (JP001) has been Approved for IND Clinical Trials

    Details:

    JP001 is a dual autophagy modulator being developed by HebaBiz Biotech, which can improve tumor microenvironment (TME) and increase tumor cells' sensitivity to chemoradiotherapy.


    Lead Product(s): Siroquine,Temozolomide

    Therapeutic Area: Oncology Product Name: JP001

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnpro Biotech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 20, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search